The week of June 15, 2026 was the busiest stretch of the U.S. IPO calendar in months. Five operating companies and SPACs priced on Thursday alone — a $400 million cardiovascular biotech, a $40 million nuclear-tech float, a community bank below its range, and two SPACs — while five new S-1s hit EDGAR behind them, headlined by a $650 million filing from Brookfield-backed data-center operator Csquare (NYSE: CSQR).
Taken together, the calendar moved roughly $859 million of priced deals and another $1.35 billion of new filings in five trading days — the clearest sign yet that the post-FOMC, lower-VIX backdrop has reopened the IPO window after a sluggish spring.
Thursday’s Pricings: A Two-Tier Tape
Thursday, June 18 produced the cleanest read on what underwriters could actually clear. Biotech topped its range. Nuclear scraped through at the low end of a downwardly revised one. A community bank gave back size to get a deal done. And both SPACs walked their stated raises out the door.
| Issuer | Sector | Price | Range outcome | Deal size |
|---|---|---|---|---|
| Kardigan (KARD) | Cardio biotech | $16.00 | Upsized; top of range | ~$400M |
| Deep Fission (FISN) | SMR nuclear | $16.00 | Low end of revised range | ~$40M |
| First Carolina Financial | Community bank | $12.50 | Below range | ~$69M |
| Wilco 63 | SPAC (AI / robotics) | $10.00 | As marketed | $200M |
| Texas Ventures Acq. IV | SPAC (industrial tech) | $10.00 | As marketed | $150M |
| Total priced, June 18 | ~$859M |
Kardigan: The Week’s Marquee Deal
Kardigan, Inc. (NASDAQ: KARD) is the deal that made the week look like a reopening. The clinical-stage precision-therapeutics company sold 25 million shares at $16 — the top of its $14–$16 range — with a 3.75 million share underwriter option, taking the gross raise to roughly $400 million on full exercise.
Kardigan’s pitch is three late-stage cardiovascular programs aimed at “high-unmet” niches, a category that traditionally trades on binary clinical-readout risk rather than near-term revenue. The fact that public-market investors were willing to upsize and price at the top of the range is the meaningful capital-markets signal — biotech generalists are clearing risk capital again. The stock jumped as much as 31% on its debut session, according to post-debut reporting.
Deep Fission: The Cooling Nuclear-IPO Trade
On the other end of the tape, Deep Fission (NASDAQ: FISN) — an advanced-nuclear developer pitching small modular pressurized-water reactors installed one mile underground — priced 2.5 million shares at $16, the bottom of a downwardly revised range. The stock closed at $14.56, about 9% below its IPO price, on its first session.
That is not what nuclear IPOs looked like in 2025. After the spring 2025 run in Oklo, NuScale, and Centrus, the SMR cohort priced at progressively richer multiples. Deep Fission’s range cut, low-end print, and below-water debut suggest that the public-market premium for “we will build a reactor someday” has narrowed — and that subsequent SMR issuers (including Standard Nuclear’s new $100 million filing) will face a much tougher book-build.
The Bank, The SPACs, and the Underlying Tape
First Carolina Financial Services made it to market but had to cut size. The community-bank holding company priced at $12.50 — below its marketed range — and raised roughly $69 million against an $82.5 million target and a $454 million implied market cap. That is the classic shape of a “you can have a deal or you can have a number, not both” outcome, and a useful sanity check on regional-bank equity appetite after a brutal 2024–25 stretch for the group.
Two SPACs, Wilco 63 and Texas Ventures Acquisition IV, priced their trusts as marketed at $200 million and $150 million respectively. SPAC IPOs have been a dependable supply story all year — sponsors with credible target sectors (AI / robotics for Wilco 63, industrial tech for Texas Ventures) are still finding institutional buyers for the float, even if the merger end of the SPAC market remains tepid.
Behind the Pricings: Five New S-1s
The filings behind the priced deals matter as much as the pricings themselves — they set the next two months of supply. Five hit in three days:
| Filer | Sector | Target raise | Filing date |
|---|---|---|---|
| Csquare (CSQR) | Data centers (Brookfield-backed) | ~$650M | Jun 16 |
| Market Technology Acq. | SPAC (US equities infra) | $200M | Jun 16 |
| Albatross Acquisition | SPAC | $100M | Jun 17 |
| Standard Nuclear | SMR nuclear fuel | $100M | Jun 18 |
| Bleichroeder Acq. III (BCCQU) | SPAC (tech, NA / Europe) | $300M | Jun 18 |
| Total filed, Jun 16–18 | ~$1.35B |
The headline filer is Csquare — the Dallas-based, Brookfield-backed enterprise digital-infrastructure platform formed when Brookfield Infrastructure Partners completed its $775 million purchase of bankrupt Cyxtera and merged it with Evoque in January 2024. The combined business operates more than 80 data centers across North American and European metros with over 500 megawatts of contracted power, per the company’s own positioning.
If Csquare clears at or above its filed range, it will be the largest data-center IPO of the cycle — and a clean test of whether public-market investors are willing to pay an AI-infrastructure multiple for a colocation portfolio with a colorful balance-sheet history (Cyxtera went public via SPAC in 2021 and filed Chapter 11 in June 2023) rather than for a greenfield hyperscale developer.
The Returns Picture, In One Chart
Why The Window Is Open Now
Three crosscurrents made this week possible. First, the FOMC’s June 16–17 meeting cleared a long-running uncertainty: Chair Warsh’s first Summary of Economic Projections penciled in a 2026 hike, hawkish on the surface but explicit on direction — the kind of clarity book-building syndicates can live with. Second, the VIX has spent most of June below 17, removing the volatility premium that had been killing range-clears in April. And third, the AI-infrastructure tape has stayed bid; data-center, nuclear-adjacent, and semiconductor names are still trading at multiples that make filing economically attractive.
What this week did not prove is that the window stays open for everyone. Kardigan cleared because biotech generalists are paying for clinical-stage cardiovascular risk again — a regime that has flipped on and off twice in two years. Deep Fission’s low-end print is a reminder that pre-revenue stories are still range-shopped, and that the SMR trade has lost its premium even as it has not lost its narrative.
What’s On Deck
The marketed calendar for the week of June 22 is already on the wire. DPC Holdings, the parent of UK engine-products manufacturer Doncasters, is targeting a roughly $700 million raise at a $4.2 billion fully diluted valuation — a deal whose pricing range will become the de-facto industrial-IPO benchmark for the quarter. If Csquare hands in a quick S-1/A and prices into July, the data-center comparable set widens for the first time since DigitalBridge took Switch private in 2022.
The cleaner takeaway from the past five sessions: a calendar that produced one upsized $400 million biotech, a $650 million Brookfield infrastructure filing, and three SPAC pricings without dislocation is a calendar the rest of 2026’s would-be issuers can plan around.
Sources
- Renaissance Capital — Weekly IPO recap and calendar, week of June 15, 2026
- StockAnalysis — Recent IPOs and returns tracker
- SEC EDGAR — Public S-1 filings for Csquare, Standard Nuclear, Bleichroeder Acquisition III, Market Technology Acquisition, and Albatross Acquisition
- Reuters — Cyxtera Chapter 11 filing, June 2023
- DatacenterDynamics — Brookfield closes $775M Cyxtera acquisition, January 2024
- Federal Reserve — June 17, 2026 Summary of Economic Projections
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.